Vertex price target raised to $60 from $57 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...
The Motley Fool15d
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...
The Boston Globe19d
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.
eLife20d
Apical constriction requires patterned apical surface remodeling to synchronize cellular deformation
8354144). The equations above are based on an assumption that an adherens junction is responsible for the edge tension and it makes an arc so that its angle of incidence to the vertex is parallel with ...
Nikkei Asia27d
TikTok angles for compromise to avert U.S. sell-or-ban ultimatum
PALO ALTO, California/HONG KONG -- TikTok is attempting to hammer out a deal with the Trump administration that would resolve the sale-or-ban order while leaving control of the platform in the ...
The Motley Fool1mon
Globant's Q4 In Line With Expectations
Earnings per share were $1.75, a touch above analysts' consensus expectation of $1.74. Revenue slightly undershot expectations at $642.5 million compared to an estimate of $644 million. The ...
marketindex7mon
Vertex Minerals Ltd (VTX)
Data supplied by Morningstar and accurate on Sep 30, 2024. It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of ...